Adam Kaul, MD
Psychiatry · Midlothian, VANPI 1689653107
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Alkermes, Inc. at 35.0% of the total. Reporting peaked in 2022 at $7,468 and has fallen 83.3% since, to $1,247 in 2025. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $63.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$7K
- Neuronetics, Inc.$6K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$804
- plus $3K from 12 others
What the payments were for
- Consulting fees$5,20026%
- Travel & lodging$5,70329%
- Food & beverage$8,75144%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 15 | $6,889 |
| Neuronetics, Inc. | 5 | $5,844 |
| Neurocrine Biosciences, Inc. | 47 | $1,372 |
| AbbVie(2 entities) | 25 | $1,121 |
| Sunovion Pharmaceuticals Inc. | 71 | $1,108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $804 |
| Otsuka America Pharmaceutical, Inc. | 27 | $790 |
| Teva Pharmaceuticals USA, Inc. | 14 | $448 |
| E.r. Squibb & Sons, L.L.C. | 10 | $281 |
| Vanda Pharmaceuticals Inc. | 15 | $267 |
| Lundbeck LLC | 12 | $261 |
| Johnson & Johnson | 12 | $230 |
| Avanir Pharmaceuticals, Inc. | 7 | $116 |
| Eisai Inc. | 7 | $116 |
| Noven Therapeutics, LLC | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Merck | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$25,815
- NEUROSTAR TMS THERAPY SYSTEM$5,379
- ARISTADA$791
- INGREZZA$612
- NEUROSTAR TMS THERAPY$465
- VRAYLAR$397
- REXULTI$242
- ARISTADA INITIO$148
- CAPLYTA$125
- COBENFY$122
- Austedo XR$116
- LATUDA$114
- ABILIFY MAINTENA$101
How this compares
$19,704 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 323 | $63,118 |
| Divalproex Sodium ErDivalproex Sodium | 512 | $48,061 |
| Lurasidone Hcl | 100 | $40,484 |
| Paliperidone ErPaliperidone | 83 | $23,614 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 83 | $21,531 |
| Invega SustennaPaliperidone Palmitate | 12 | $21,498 |
| Risperidone | 1,193 | $21,461 |
| Clozapine | 160 | $19,704 |
| Quetiapine Fumarate | 651 | $17,395 |
| Oxcarbazepine | 232 | $17,203 |
| Chlorpromazine Hcl | 62 | $17,051 |
| Divalproex Sodium | 340 | $13,278 |
| Trazodone Hcl | 598 | $13,167 |
| Benztropine Mesylate | 785 | $11,712 |
| Olanzapine | 435 | $10,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $230 | $21,49812 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $448 | $3,52112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Midlothian
- Rehan SaleemMidlothian$28K
- Kemberly ClarkMidlothian$11K
- Jagdeep KahlonMidlothian$8K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
- Anita ClaytonCharlottesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.